| P50 | author | Paul Galatsis | Q56420928 |
| P2860 | cites work | Leucine-rich repeat kinase 2 binds to neuronal vesicles through protein interactions mediated by its C-terminal WD40 domain | Q24293453 |
| | 14-3-3 binding to LRRK2 is disrupted by multiple Parkinson's disease-associated mutations and regulates cytoplasmic localization | Q24339094 |
| | Discovery and preclinical profiling of 3-[4-(morpholin-4-yl)-7H-pyrrolo[2,3-d]pyrimidin-5-yl]benzonitrile (PF-06447475), a highly potent, selective, brain penetrant, and in vivo active LRRK2 kinase inhibitor | Q27695740 |
| | Structural model of the dimeric Parkinson's protein LRRK2 reveals a compact architecture involving distant interdomain contacts | Q28116245 |
| | Phosphoproteomics reveals that Parkinson's disease kinase LRRK2 regulates a subset of Rab GTPases | Q28119192 |
| | Mutations in LRRK2 cause autosomal-dominant parkinsonism with pleomorphic pathology | Q28131833 |
| | Cloning of the gene containing mutations that cause PARK8-linked Parkinson's disease | Q28292932 |
| | A new locus for Parkinson's disease (PARK8) maps to chromosome 12p11.2-q13.1. | Q34118222 |
| | Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease: a pooled analysis | Q35195815 |
| | Association of LRRK2 exonic variants with susceptibility to Parkinson's disease: a case-control study | Q35525896 |
| | Leucine-rich Repeat Kinase 2 (LRRK2) Pharmacological Inhibition Abates α-Synuclein Gene-induced Neurodegeneration | Q35925767 |
| | The role of LRRK2 in inflammatory bowel disease | Q36079983 |
| | G2019S-LRRK2 Expression Augments α-Synuclein Sequestration into Inclusions in Neurons. | Q37096048 |
| | LRRK2 in Parkinson's disease: genetic and clinical studies from patients | Q37608624 |
| | Association studies of sporadic Parkinson's disease in the genomic era. | Q37645620 |
| | The pathomechanisms underlying Parkinson's disease | Q38182660 |
| | Type II kinase inhibitors show an unexpected inhibition mode against Parkinson's disease-linked LRRK2 mutant G2019S. | Q38520438 |
| | MLi-2, a Potent, Selective, and Centrally Active Compound for Exploring the Therapeutic Potential and Safety of LRRK2 Kinase Inhibition. | Q38832432 |
| | Moving beyond rules: the development of a central nervous system multiparameter optimization (CNS MPO) approach to enable alignment of druglike properties | Q39693636 |
| | Association of the LRRK2 genetic polymorphisms with leprosy in Han Chinese from Southwest China | Q41592813 |
| | Development of an enzyme-linked immunosorbent assay for detection of cellular and in vivo LRRK2 S935 phosphorylation | Q41812724 |
| | Surfactant secretion in LRRK2 knock-out rats: changes in lamellar body morphology and rate of exocytosis. | Q41882309 |
| | Effect of selective LRRK2 kinase inhibition on nonhuman primate lung. | Q46777308 |
| | Ser1292 autophosphorylation is an indicator of LRRK2 kinase activity and contributes to the cellular effects of PD mutations | Q48252778 |
| | Central Nervous System Multiparameter Optimization Desirability: Application in Drug Discovery | Q48825227 |
| | Potent, selective and orally bioavailable leucine-rich repeat kinase 2 (LRRK2) inhibitors. | Q54198929 |
| P433 | issue | 6 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 667-676 | |
| P577 | publication date | 2017-01-24 | |
| P1433 | published in | Expert Opinion on Therapeutic Patents | Q5421213 |
| P1476 | title | Leucine-rich repeat kinase 2 inhibitors: a patent review (2014-2016). | |
| P478 | volume | 27 | |